[1] AKINYEMIJU T,ABERA S,AHMED M,et al.The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global,regional,and national level:results from the Global Burden of Disease Study 2015[J].JAMA Oncol,2017,3(12):1683-1691.
[2] CHENG AL,KANG YK,CHEN Z,et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phase Ⅲ randomised,double-blind,placebo-controlled trial[J].Lancet Oncol,2009,10(1):25-34.
[3] LLOVET JM,RICCI S,MAZZAFERRO V,et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med,2008,359(4):378-390.
[4] LAI CL,RATZIU V,YUEN MF,et al.Viral hepatitis B[J].Lancet,2003,362(9401):2089-2094.
[5] OMATA M,CHENG AL,KOKUDO N,et al.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma:a 2017 update[J].Hepatol Int,2017,11(4):317-370.
[6] BRUIX J,REIG M,SHERMAN M.Evidence-based diagnosis,staging,and treatment of patients with hepatocellular carcinoma[J].Gastroenterology,2016,150(4):835-853.
[7] CHEN J,JIN R,ZHAO J,et al.Potential molecular,cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma[J].Cancer Lett,2015,367(1):1-11.
[8] JACKSON R,PSARELLI EE,BERHANE S,et al.Impact of viral status on survival in patients receiving sorafenib for advanced hepatocellular cancer:a meta-analysis of randomized phase Ⅲ trials[J].J Clin Oncol,2017,35(6):622-628.
[9] EL-SERAG HB.Hepatocellular carcinoma[J].N Engl J Med,2011,365(12):1118-1127.
[10] PARSONS HM,CHU Q,KARLITZ JJ,et al.Adoption of sorafenib for the treatment of advanced-stage hepatocellular carcinoma in oncology practices in the united states[J].Liver Cancer,2017,6(3):216-226.
[11] PARK JW,CHEN M,COLOMBO M,et al.Global patterns of hepatocellular carcinoma management from diagnosis to death:the BRIDGE Study[J].Liver Int,2015,35(9):2155-2166.
[12] BRUIX J,SHERMAN M.Management of hepatocellular carcinoma:an update[J].Hepatology,2011,53(3):1020-1022.
[13] BRUIX J,GORES GJ,MAZZAFERRO V.Hepatocellular carcinoma:clinical frontiers and perspectives[J].Gut,2014,63(5):844-855.
[14] DAWKINS J,WEBSTER RM.The hepatocellular carcinoma market[J].Nat Rev Drug Discov,2018.
[15] BRUIX J,QIN S,MERLE P,et al.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE):a randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet,2017,389(10064):56-66.
[16] EL-KHOUEIRY AB,SANGRO B,YAU T,et al.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040):an open-label,non-comparative,phase 1/2 dose escalation and expansion trial[J].Lancet,2017,389(10088):2492-2502.
[17] EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER.EASL Clinical Practice Guidelines:management of hepatocellular carcinoma[J].J Hepatol,2018,69(1):182-236.
[18] BENSON AR,D'ANGELICA MI,ABBOTT DE,et al.NCCN Guidelines Insights:Hepatobiliary Cancers,Version 1.2017[J].J Natl Compr Canc Netw,2017,15(5):563-573.
[19] HATOOKA M,KAWAOKA T,AIKATA H,et al.Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55):an open label,non-comparative,phase Ⅱ trial[J].BMC Cancer,2018,18(1):633.
[20] IKEDA M,SHIMIZU S,SATO T,et al.Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma:randomized phase Ⅱ trial[J].Ann Oncol,2016,27(11):2090-2096.
[21] FORNARO L,VIVALDI C,LORENZONI G,et al.Moving beyond sorafenib alone in advanced hepatocellular carcinoma:is hepatic arterial infusion chemotherapy the best option?[J].Ann Oncol,2017,28(3):667.
[22] IKEDA M,SHIMIZU S,SATO T,et al.Reply to the Letter to the editor' Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus Sorafenib for advanced hepatocellular carcinoma:randomized phase Ⅱ trial' by Fornaro et al[J].Ann Oncol,2017,28(4):903-904.
[23] SONG DS,SONG MJ,BAE SH,et al.A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis[J].J Gastroenterol,2015,50(4):445-454.
[24] KUDO M,UESHIMA K,YOKOSUKA O,et al.Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS):a randomised,open label,phase 3 trial[J].Lancet Gastroenterol Hepatol,2018,3(6):424-432.
[25] SAEKI I,YAMASAKI T,MAEDA M,et al.Treatment strategies for advanced hepatocellular carcinoma:Sorafenibvs hepatic arterial infusion chemotherapy[J].World J Hepatol,2018,10(9):571-584.
[26] OBI S,SATO S,KAWAI T.Current status of hepatic arterial infusion chemotherapy[J].Liver Cancer,2015,4(3):188-199.
[27] YAMASHITA T,ARAI K,SUNAGOZAKA H,et al.Randomized,phase Ⅱ study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma[J].Oncology,2011,81(5-6):281-290.
[28] NAGANO H,WADA H,KOBAYASHI S,et al.Long-term outcome of combined interferon-alpha and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis[J].Oncology,2011,80(1-2):63-69.
[29] OTA H,NAGANO H,SAKON M,et al.Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil;role of type 1 interferon receptor expression[J].Br J Cancer,2005,93(5):557-564.
[30] IKEDA M,OKUSAKA T,FURUSE J,et al.A multi-institutional phase Ⅱ trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis[J].Cancer Chemother Pharmacol,2013,72(2):463-470.
[31] MONDEN M,SAKON M,SAKATA Y,et al.5-fluorouracil arterial infusion + interferon therapy for highly advanced hepatocellular carcinoma:a multicenter,randomized,phase Ⅱ study[J].Hepatol Res,2012,42(2):150-165.
[32] OBI S,YOSHIDA H,TOUNE R,et al.Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion[J].Cancer,2006,106(9):1990-1997.
[33] UESHIMA K,KUDO M,TANAKA M,et al.Phase Ⅰ/Ⅱ study of sorafenib in combination with hepatic arterial infusion chemotherapy using low-dose cisplatin and 5-fluorouracil[J].Liver Cancer,2015,4(4):263-273.
[34] NAKANO M,NIIZEKI T,NAGAMATSU H,et al.Clinical effects and safety of intra arterial infusion therapy of cisplatin suspension in lipiodol combined with 5 fluorouracil versus sorafenib,for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra hepatic spread:a prospective cohort study[J].Mol Clin Oncol,2017,7(6):1013-1020.
[35] SAEKI I,YAMASAKI T,TANABE N,et al.A new therapeutic assessment score for advanced hepatocellular carcinoma patients receiving hepatic arterial infusion chemotherapy[J].PLoS One,2015,10(5):e126649.
[36] KAWAOKA T,AIKATA H,KOBAYASHI T,et al.Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma[J].Hepatol Res,2018,48(13):1118-1130.
[37] NOUSO K,MIYAHARA K,UCHIDA D,et al.Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan[J].Br J Cancer,2013,109(7):1904-1907.
[38] YOSHIKAWA M,ONO N,YODONO H,et al.Phase Ⅱ study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma[J].Hepatol Res,2008,38(5):474-483.
[39] KONDO M,MORIMOTO M,NUMATA K,et al.Hepatic arterial infusion therapy with a fine powder formulation of cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis[J].Jpn J Clin Oncol,2011,41(1):69-75.
[40] IWASA S,IKEDA M,OKUSAKA T,et al.Transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization[J].Jpn J Clin Oncol,2011,41(6):770-775.
[41] KONDO M,MORIMOTO M,ISHII T,et al.Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization:a propensity score-based weighting[J].J Dig Dis,2015,16(3):143-151.
[42] KIM BK,PARK JY,CHOI HJ,et al.Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma[J].J Cancer Res Clin Oncol,2011,137(4):659-667.
[43] ISHIKAWA T,KUBOTA T,ABE S,et al.Hepatic arterial infusion chemotherapy with cisplatin before radical local treatment of early hepatocellular carcinoma (JIS score 0/1) improves survival[J].Ann Oncol,2014,25(7):1379-1384.
[44] QIN S,BAI Y,LIM H Y,et al.Randomized,multicenter,open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J].J Clin Oncol,2013,31(28):3501-3508.
[45] HE MK,LE Y,LI Q J,et al.Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma:a prospective non-randomized study[J].Chin J Cancer,2017,36(1):83.
[46] LYU N,LIN Y,KONG Y,et al.FOXAI:a phase Ⅱ trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma[J].Gut,2018,67(2):391-395.
[47] LYU N,KONG Y,MU L,et al.Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs.sorafenib for advanced hepatocellular carcinoma[J].J Hepatol,2018,69(1):60-69.
[48] ANDO E,TANAKA M,YAMASHITA F,et al.Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis:analysis of 48 cases[J].Cancer,2002,95(3):588-595.
[49] MIYAKI D,AIKATA H,HONDA Y,et al.Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to Child-Pugh classification[J].J Gastroenterol Hepatol,2012,27(12):1850-1857.
[50] MIYAKI D,KAWAOKA T,AIKATA H,et al.Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of response evaluation criteria in solid tumors and tumor markers[J].J Gastroenterol Hepatol,2015,30(4):726-732.
[51] NIIZEKI T,SUMIE S,TORIMURA T,et al.Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy[J].J Gastroenterol,2012,47(6):686-695.
[52] MANTOVANI A,ALLAVENA P,SICA A,et al.Cancer-related inflammation[J].Nature,2008,454(7203):436-444.
[53] TAJIRI K,KAWAI K,MINEMURA M,et al.Neutrophil/lymphocyte ratio as a prognostic indicator of hepatic arterial infusion chemotherapy with arterial cisplatin plus continuous 5-fluorouracil[J].Hepatol Res,2015,45(7):755-763.
[54] TERASHIMA T,YAMASHITA T,IIDA N,et al.Blood neutrophil to lymphocyte ratio as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy[J].Hepatol Res,2015,45(9):949-959.